Cellular Alterations in Immune Checkpoint Inhibitor Therapy-Related Cardiac Dysfunction
© 2024. The Author(s)..
PURPOSE OF REVIEW: Immune checkpoint inhibitor (ICI) therapy has emerged as a pivotal advancement in cancer treatment, but the widespread adoption has given rise to a growing number of reports detailing significant cardiovascular toxicity. This review concentrates on elucidating the mechanisms behind ICI-related cardiovascular complications, emphasizing preclinical and mechanistic data.
RECENT FINDINGS: Accumulating evidence indicates a more significant role of immune checkpoints in maintaining cardiac integrity than previously understood, and new key scientific data are available to improve our understanding of ICI-related cardiovascular toxicity, including hidden cardiotoxicity. New avenues for innovative concepts are hypothesized, and opportunities to leverage the knowledge from ICI-therapy for pioneering approaches in related scientific domains can be derived from the latest scientific projects. Cardiotoxicity from ICI therapy is a paramount challenge for cardio-oncology. Understanding the underlying effects builds the foundation for tailored cardioprotective approaches in the growing collective at risk for severe cardiovascular complications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Current heart failure reports - (2024) vom: 02. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Michel, Lars [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cardio-oncology |
|---|
| Anmerkungen: |
Date Revised 02.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1007/s11897-024-00652-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36920185X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36920185X | ||
| 003 | DE-627 | ||
| 005 | 20240302233037.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240302s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11897-024-00652-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1314.xml |
| 035 | |a (DE-627)NLM36920185X | ||
| 035 | |a (NLM)38430308 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Michel, Lars |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cellular Alterations in Immune Checkpoint Inhibitor Therapy-Related Cardiac Dysfunction |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a PURPOSE OF REVIEW: Immune checkpoint inhibitor (ICI) therapy has emerged as a pivotal advancement in cancer treatment, but the widespread adoption has given rise to a growing number of reports detailing significant cardiovascular toxicity. This review concentrates on elucidating the mechanisms behind ICI-related cardiovascular complications, emphasizing preclinical and mechanistic data | ||
| 520 | |a RECENT FINDINGS: Accumulating evidence indicates a more significant role of immune checkpoints in maintaining cardiac integrity than previously understood, and new key scientific data are available to improve our understanding of ICI-related cardiovascular toxicity, including hidden cardiotoxicity. New avenues for innovative concepts are hypothesized, and opportunities to leverage the knowledge from ICI-therapy for pioneering approaches in related scientific domains can be derived from the latest scientific projects. Cardiotoxicity from ICI therapy is a paramount challenge for cardio-oncology. Understanding the underlying effects builds the foundation for tailored cardioprotective approaches in the growing collective at risk for severe cardiovascular complications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cardio-oncology | |
| 650 | 4 | |a Cardiotoxicity | |
| 650 | 4 | |a Hidden cardiotoxicity | |
| 650 | 4 | |a Immune checkpoint inhibitor | |
| 650 | 4 | |a Immune-related adverse events | |
| 650 | 4 | |a Programmed cell death protein 1 | |
| 700 | 1 | |a Ferdinandy, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Rassaf, Tienush |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current heart failure reports |d 2004 |g (2024) vom: 02. März |w (DE-627)NLM156716283 |x 1546-9549 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:02 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11897-024-00652-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 02 |c 03 | ||